Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Synercid
Active Ingredients: Dalfopristin 350mg
Quinupristin 150mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Catalytica Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This consent is valid for 2 years from 20 June 2002.
Dated this 2nd day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).